ストックスクリーナーアプリを入手
59.73
0.30%
0.18
アフターアワーズ：
59.73
前日終値:
$59.55
開ける：
$58.8
24時間の取引高:
2.17M
Relative Volume:
1.09
時価総額：
$12.01B
収益：
$4.08B
当期純損益:
$32.48M
株価収益率:
426.64
EPS:
0.14
ネットキャッシュフロー:
$16.80M
1週間 パフォーマンス:
-3.71%
1か月 パフォーマンス:
+4.84%
6か月 パフォーマンス:
-28.36%
1年 パフォーマンス:
+11.62%
1日の値動き範囲:
$57.77
$59.99
1週間の範囲:
$57.77
$62.87
52週間の値動き範囲:
$52.81
$83.95
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
59.73 | 12.01B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress - MyChesCo
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte to Present at Upcoming Investor Conference - Business Wire
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga
Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus
Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus
BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus
Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus
Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey
Incyte: Q1 Earnings Snapshot - CT Insider
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com
BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace
Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus
Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com
Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus
Incyte Q1 Results Top Estimates - Nasdaq
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus
Incyte earnings beat by $0.12, revenue topped estimates - Investing.com
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers - Barchart.com
Incyte Reports 2025 First Quarter Financial Results - TradingView
Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus
Incyte (INCY) Q1 Earnings Report Preview: What To Look For - Barchart.com
Incyte to Highlight Early-Stage Oncology Data at American Associ - GuruFocus
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
5.73%
1.07%
大文字化:
|
ボリューム (24 時間):